Differential aminoacylase expression in neuroblastoma

Department of Anatomy and Neurobiology, University of Vermont College of Medicine, Burlington, VT 05405, USA.
International Journal of Cancer (Impact Factor: 5.01). 09/2011; 129(6):1322-30. DOI: 10.1002/ijc.25798
Source: PubMed

ABSTRACT Neuroblastoma, a cancer of the sympathetic nervous system, is the most common extracranial solid tumor in children. MYCN amplification and increased BDNF/TrkB signaling are features of high-risk tumors; yet, only ˜25% of malignant tumors display these features. Thus, the identification of additional biomarkers and therapeutic targets is essential. As aminoacylase 1 (ACY1), an amino acid deacetylase, is a putative tumor suppressor in small cell lung and renal cell carcinomas, we investigated whether it or the other family members aspartoacylase (ASPA, aminoacylase 2) or aminoacylase 3 (ACY3) could serve a similar function in neuroblastoma. Aminoacylase expression was examined in TrkB-positive, MYCN-amplified (SMS-KCNR and SK-N-BE) and TrkB-negative, non-MYCN-amplified (SK-N-AS, SK-N-SH, SH-SY5Y and SH-EP) neuroblastoma cell lines. Each aminoacylase exhibited distinct spatial localization (i.e., cytosolic ACY1, membrane-associated ASPA and nuclear ACY3). When SK-N-SH cells were treated with neural differentiation agents (e.g., retinoic acid and cAMP) in media containing 10% serum, ACY1 was the only aminoacylase whose expression was upregulated. ASPA was primarily expressed in SH-EP cells of a glial sublineage. ACY3 was more highly expressed in the TrkB-positive, MYCN-amplified lines. All three aminoacylases were expressed in normal human adrenal gland, a common site of neuroblastoma origin, but only ACY1 and ACY3 displayed detectable expression in primary neuroblastoma tumor. Bioinformatics data mining of Kaplan-Meier survival revealed that high ACY3 expression is correlated with poor prognosis, whereas low expression of ACY1 or ASPA is correlated with poor prognosis. These data suggest that aminoacylase expression is dysregulated in neuroblastoma.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: High-risk neuroblastoma is an aggressive malignancy with high rates of treatment failure. We evaluated genetic variants associated with in vitro sensitivity to two derivatives of cyclophosphamide for association with clinical response in a separate replication cohort of neuroblastoma patients (n=2,709). Lymphoblastoid cell lines (LCLs) were exposed to increasing concentrations of 4-hydroperoxycyclophosphamide [4HC n=422] and phosphoramide mustard [PM n=428] to determine sensitivity. Genome-wide association studies (GWAS) were performed to identify single nucleotide polymorphisms (SNPs) associated with 4HC and PM sensitivity. SNPs consistently associated with LCL sensitivity were analyzed for associations with event-free survival in patients. Two linked SNPs, rs9908694 and rs1453560, were found to be associated with PM sensitivity in LCLs across populations and were associated with event-free survival in all patients (P=0.01) and within the high-risk subset (P=0.05). Our study highlights the value of cell-based models to identify candidate variants that may predict response to treatment in patients with cancer.Clinical Pharmacology & Therapeutics (2014); accepted article preview online 18 February 2014 doi:10.1038/clpt.2014.37.
    Clinical Pharmacology &#38 Therapeutics 02/2014; 95(6). DOI:10.1038/clpt.2014.37 · 7.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies were undertaken to determine whether ERK oscillations regulate a unique subset of genes in human keratinocytes and subsequently, whether the p38 stress response inhibits ERK oscillations. A DNA microarray identified many genes that were unique to ERK oscillations, and network reconstruction predicted an important role for the mediator complex subunit 1 (MED1) node in mediating ERK oscillation-dependent gene expression. Increased ERK-dependent phosphorylation of MED1 was observed in oscillating cells compared to non-oscillating counterparts as validation. Treatment of keratinocytes with a p38 inhibitor (SB203580) increased ERK oscillation amplitudes and MED1 and phospho-MED1 protein levels. Bromate is a probable human carcinogen that activates p38. Bromate inhibited ERK oscillations in human keratinocytes and JB6 cells and induced an increase in phospho-p38 and decrease in phospho-MED1 protein levels. Treatment of normal rat kidney cells and primary salivary gland epithelial cells with bromate decreased phospho-MED1 levels in a reversible fashion upon treatment with p38 inhibitors (SB202190; SB203580). Our results indicate that oscillatory behavior in the ERK pathway alters homeostatic gene regulation patterns and that the cellular response to perturbation may manifest differently in oscillating vs non-oscillating cells.
    Chemical Research in Toxicology 07/2014; 27(9). DOI:10.1021/tx500085u · 4.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present work aimed to investigate the expression and role of aminoacylase 1 (ACY1) in hepatocellular carcinoma (HCC) based on a proteomic study. The study results revealed that the expression of ACY1 was much lower in HCC tissues. ACY1 expression significantly correlated with the serum alpha fetoprotein level and tumor invasiveness. The knockdown of ACY1 in SMMC7721 cells promoted cell viability and invasiveness. In contrast, the restoration of ACY1 in BEL7402 cells inhibited cell viability and invasiveness. Further studies indicated that the knockdown of ACY1 increased the protein expression of transforming growth factor beta 1 and extracellular signal-regulated kinase 1 expression. The study’s results indicated that ACY1 acts as a tumor suppressor in HCC.
    Cancer Letters 08/2014; DOI:10.1016/j.canlet.2014.05.001 · 5.02 Impact Factor

Full-text (2 Sources)

Available from
Sep 19, 2014